Core Viewpoint - The company is expected to see a gradual recovery in sales in the second half of the year, following a rebound in performance after a temporary setback due to a public relations incident in May [1][2] Group 1: Sales Performance - After the public relations incident on May 24, the company's sales were impacted but remain manageable, with a notable recovery in July as some top influencers resumed live streaming the company's products [1] - Data from Jiuqian shows that in July, the company's GMV on Tmall and Douyin increased by 70% and 17% year-on-year, respectively, indicating a positive sales trend [1] - The company ranked 16th in Tmall's beauty category during the 618 shopping festival, up from 12th place in 2024, suggesting a strong market presence [1] Group 2: Product Development and Market Strategy - The company has a well-established research foundation in the collagen field, with a focus on high-quality product offerings that enhance brand recognition [1] - The product matrix includes medical devices, collagen repair products, and targeted series, with the collagen stick serving as a flagship product to stabilize market share [2] - The company is actively enhancing its anti-aging image through increased investment in core products and new product launches, which are expected to drive growth [2] Group 3: Financial Projections - The company is projected to achieve revenues of 6.86 billion, 8.49 billion, and 10.21 billion yuan from 2025 to 2027, with net profits of 2.43 billion, 2.95 billion, and 3.49 billion yuan, respectively [2] - The corresponding price-to-earnings ratios are expected to be 25.2, 20.7, and 17.5 times for the same period, indicating a favorable valuation outlook [2]
巨子生物(02367.HK)：达播恢复数据环比回暖 看好H2销售逐步回升